Fiche société
University of Colorado, Denver
Traitements, essais et publications liés.
Traitements39programmes
Essais20liés
Publications23liées
SourceDBlocale
Traitements
39| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 3, 4-DiaminopyridineTo learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS). | Myasthénie | À vérifier | À vérifier | United States | À vérifier |
| adaptive DBS (aDBS)This is an interventional study of a cohort of patients with PD treated with DBS, and already utilizing adaptive DBS (dual threshold mode). In Aim 1, we will obtain baseline sleep and basal ganglia physiology data to inform aDBS parameter changes. Aim 2 involves 15 nights of in-home monitoring of subjective and objective sleep quality, during which participants will use 3 different sleep-tailored aDBS settings at night only. Participant preference among these 3 settings will determined the 'optimized sleep-tailored aDBS mode'. Participants will undergo repeat polysomnography, while in the optimized sleep-tailored aDBS mode, to compare aDBS behavior and sleep architecture to the baseline (Aim 1) sleep study. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| aDBSThe investigators conduct a prospective study to evaluate the effects of exercise on Parkinson's Disease brain biomarkers detected with the PerceptTM PC neurostimulator. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| brain electrodeThis study is being done to the determine the ability and utility of using the Neuropixels probes in the human brain. A Neuropixels probe will be inserted into and removed from the brain of awake human patients who are undergoing awake Deep Brain Stimulation (DBS) surgery. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| CD19x22 CAR TThis study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL. | SEP | Phase 1 | Immunomodulation | United States | À vérifier |
| Clemastine Fumarate Combined With Engineered SoundThe goal of this clinical trial is to determine the efficacy of Clemastine Fumarate in the presence of engineered sound to treat age-related central auditory processing disorder (CAPD). This disorder impacts 800M patients worldwide, including \~1/3 people over 40 years of age and \~1/2 people over 65, resulting in an inability to hear in noisy environments. The primary hypothesis this study aims to test is: engineered sound, driving localized neural circuit activity, will enable Clemastine Fumarate to mature Oligodendrocyte cells and thus remyelinate these activated neural circuits. This Localized Oligodendrocyte Optimization Therapy (LOOT) was highly effective in preclinical animal studies so this clinical trial aims to answer if this therapy will translate to humans. The study is an adaptive design intended to compare the efficacy of the drug in the presence or absence of the engineered sound for improving hearing in noise ability. Trial participants will be tested for hearing thresholds and ability to isolate a sound signal from background noise. If they meet the inclusion criteria, they will be enrolled into one of the four arms of the study and undergo the proposed one-month treatment (drug and sound or respective placebos). After the treatment period, trial participants will be tested again for hearing thresholds and their ability to isolate s sound source of interest from background noise. The hypothesis to be tested in this clinical trial is that the one-month treatment will significantly improve the participant's ability to isolate a sound source of interest from background noise. The design has four arms, drug+sound, placebo+sound, drug+white noise, and placebo+white noise. Based on our preclinical data, control arms are all expected to show identical results, thus our adaptive design includes interim analyses to allow for dropping of two of the three placebo arms should the preclinical results be replicated as anticipated. We will also monitor each participant's general health during the duration of the clinical trial, which will be done by performing a number of blood tests, an EKG and a general physical before and after the one-month treatment period. We expect no significant changes since participants will take the drug for the one-month period at dosages already demonstrated safe in several Phase II studies of multiple sclerosis. Similarly, the engineered sound will be listened to for one hour per day during this month at sound intensities well below threshold that might cause noise-induced hearing damage. | SEP | Phase 1/2 | Remyélinisation | United States | À vérifier |
| Clemastine Fumarate Combined With Pink NoiseThe goal of this clinical trial is to determine the efficacy of Clemastine Fumarate in the presence of engineered sound to treat age-related central auditory processing disorder (CAPD). This disorder impacts 800M patients worldwide, including \~1/3 people over 40 years of age and \~1/2 people over 65, resulting in an inability to hear in noisy environments. The primary hypothesis this study aims to test is: engineered sound, driving localized neural circuit activity, will enable Clemastine Fumarate to mature Oligodendrocyte cells and thus remyelinate these activated neural circuits. This Localized Oligodendrocyte Optimization Therapy (LOOT) was highly effective in preclinical animal studies so this clinical trial aims to answer if this therapy will translate to humans. The study is an adaptive design intended to compare the efficacy of the drug in the presence or absence of the engineered sound for improving hearing in noise ability. Trial participants will be tested for hearing thresholds and ability to isolate a sound signal from background noise. If they meet the inclusion criteria, they will be enrolled into one of the four arms of the study and undergo the proposed one-month treatment (drug and sound or respective placebos). After the treatment period, trial participants will be tested again for hearing thresholds and their ability to isolate s sound source of interest from background noise. The hypothesis to be tested in this clinical trial is that the one-month treatment will significantly improve the participant's ability to isolate a sound source of interest from background noise. The design has four arms, drug+sound, placebo+sound, drug+white noise, and placebo+white noise. Based on our preclinical data, control arms are all expected to show identical results, thus our adaptive design includes interim analyses to allow for dropping of two of the three placebo arms should the preclinical results be replicated as anticipated. We will also monitor each participant's general health during the duration of the clinical trial, which will be done by performing a number of blood tests, an EKG and a general physical before and after the one-month treatment period. We expect no significant changes since participants will take the drug for the one-month period at dosages already demonstrated safe in several Phase II studies of multiple sclerosis. Similarly, the engineered sound will be listened to for one hour per day during this month at sound intensities well below threshold that might cause noise-induced hearing damage. | SEP | Phase 1/2 | Remyélinisation | United States | À vérifier |
| Closed Loop Trans-Auricular Vagus Nerve Stimulation SystemThe goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function. The main questions it aims to answer are: * Is stimulating the vagus nerve safe and feasible after demyelinating episodes? * Does a paired motor task with vagus nerve stimulation improve motor function with someone who has multiple sclerosis? Researchers will compare active vagus nerve stimulation to a sham stimulation to see if the paired vagus nerve stimulation can improve motor control. Participants will: * Come in for study visits over a six month period. Study visits are three times weekly for the first month, then single follow up visits at two, three, and six months. * During study visits, participants will complete 30 minutes of the paired vagus nerve stimulation with a motor task, specifically the grooved peg test. * At various timepoints throughout the study, motor, disability, and neurophysiological assessments will be administered, including the Timed 25-Foot Walk Test, Expanded Disability Status Scale (EDSS), Upper Extremity portion of the Fugl-Meyer Assessment, Dellon-Modified Moberg Pick-Up Test, Multiple Sclerosis Impact Scale-29 (MSIS-29), motor evoked potentials (MEPs), and visual evoked potentials (VEPs). MRI assessments will also be performed to evaluate exploratory imaging metrics of potential remyelinative efficacy. | SEP | Non applicable | Remyélinisation | United States | À vérifier |
| HEADS-UP — Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding PainThe goal of this study (supported by and included in the NIH HEAL Initiative: https://heal.nih.gov/) is to learn if a fully virtual study comparing two telehealth group interventions for adolescents with migraine is feasible and acceptable: 1. Telehealth group mindfulness-based intervention 2. Telehealth group headache education | Migraine | Non applicable | Traitement symptomatique | United States | À vérifier |
| Ocrelizumab at homeThe goal is to assess the safety and effectiveness of home ocrelizumab infusion. | SEP | Phase 4 | À vérifier | United States | À vérifier |
| OzanimodThis study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod. The study will collect and review reported cases of PML to describe patient characteristics and estimate how often PML occurs among people treated with ozanimod. Researchers will assess factors that may be associated with the occurrence of PML, such as age, duration of ozanimod exposure, prior immunosuppressant use, lymphopenia, and JCV antibody status . | SEP | Phase 4 | À vérifier | United States | À vérifier |
| Risk Factors in Early Multiple SclerosisThe central hypothesis of this protocol is that it is possible, using First Degree Relatives (FDRs) of patients with Multiple Sclerosis (MS) and assessing a variety of both known and unknown risk factors for MS, to define a risk algorithm for earliest signs of development of MS. The plan will be to do an abbreviated brain Magnetic Resonance Imaging (MRI) scan in asymptomatic, young FDRs, analyze blood for a variety of immunological, genetic, neuroaxonal damage, metabolic, viral serology and other markers, and have FDRs fill out a detailed bioscreen questionnaire about lifestyle factors and perform a cognitive screening test. The investigators will then compare the results of the various blood/other studies in FDRs with and without an MRI showing signs signs concerning for MS, as well as age-and sex-matched NON-FDRs who will have blood drawn and fill out the questionnaire. With this preliminary cross-sectional study, the investigators hope to begin to identify a risk stratification model for those at highest risk of developing MS, ie FDRs, with a long-term goal of developing a longitudinal study to increase sensitivity and specificity of the risk model. | SEP | À vérifier | Neuroprotection + Traitement symptomatique | United States | À vérifier |
| Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg/dL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint. | Maladie coronarienne | Non applicable | United States | À vérifier | |
| Sweat Evaporimeter MeasurementThe investigators hypothesize that measurement of beta adrenergic induced sweat rate using an evaporimeter can accurately and reliably determine different levels of CFTR dysfunction within a spectrum of patients expressing various degrees of cystic fibrosis disease. The investigators overall goal is to determine whether the evaporimeter technique of measuring beta-adrenergic induced sweat rate is capable of accurately and reliably identifying different levels of CFTR dysfunction, as a prerequisite before advancing this technique as biomarker assay into clinical trials. | SEP | Non applicable | À vérifier | United States | À vérifier |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and AtorvastatinThe goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is: * Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment * Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages. * Participants will take atorvastatin (daily pill) alongside their standard treatment. | Cancer | Phase 2 | United States | À vérifier | |
| TecfideraThe investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy. | SEP | À vérifier | Immunomodulation | United States | À vérifier |
| Temporary implatation of large-scale intracranial electrode.This study is being done to the determine the ability and utility of using the Neuropixels probes in the human brain. A Neuropixels probe will be inserted into and removed from the brain of awake human patients who are undergoing awake Deep Brain Stimulation (DBS) surgery. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| ULTRA-DM/MDD — Using Learning Teams for Reflective Adaptation for Diabetes and DepressionThe study will randomize 54 primary care practices to two intervention and a comparison groups. Both interventions will involve an on-site Improvement Facilitator who will assist the practice in forming an Improvement Team, using rapid-cycle tests of change, and implementing chronic care office systems for type 2 diabetes and depression. One intervention is based on complexity science and the other is a traditional QI intervention. | Hypertension | NA | À vérifier | United States | À vérifier |
| Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment SyndromeThe purpose of this study is to investigate high frequency ultrasound as a future modality for the diagnosis of chronic exertional compartment syndrome (CECS). The results of the ultrasound will help determine if there are any significant radiologic findings or patterns seen in patients with CECS. | Myopathies | À vérifier | À vérifier | United States | À vérifier |
| VumerityThe investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy. | SEP | À vérifier | Immunomodulation | United States | À vérifier |
| Risk Factors in Early Multiple SclerosisThe central hypothesis of this protocol is that it is possible, using First Degree Relatives (FDRs) of patients with Multiple Sclerosis (MS) and assessing a variety of both known and unknown risk factors for MS, to define a risk algorithm for earliest signs of development of MS. The plan will be to do an abbreviated brain Magnetic Resonance Imaging (MRI) scan in asymptomatic, young FDRs, analyze blood for a variety of immunological, genetic, neuroaxonal damage, metabolic, viral serology and other markers, and have FDRs fill out a detailed bioscreen questionnaire about lifestyle factors and perform a cognitive screening test. The investigators will then compare the results of the various blood/other studies in FDRs with and without an MRI showing signs signs concerning for MS, as well as age-and sex-matched NON-FDRs who will have blood drawn and fill out the questionnaire. With this preliminary cross-sectional study, the investigators hope to begin to identify a risk stratification model for those at highest risk of developing MS, ie FDRs, with a long-term goal of developing a longitudinal study to increase sensitivity and specificity of the risk model. | SEP | À vérifier | Neuroprotection + Traitement symptomatique | United States | À vérifier |
| 3, 4-DiaminopyridineTo learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS). | Myasthénie | À vérifier | À vérifier | United States | À vérifier |
| Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment SyndromeThe purpose of this study is to investigate high frequency ultrasound as a future modality for the diagnosis of chronic exertional compartment syndrome (CECS). The results of the ultrasound will help determine if there are any significant radiologic findings or patterns seen in patients with CECS. | Myopathies | À vérifier | À vérifier | United States | À vérifier |
| ULTRA-DM/MDD — Using Learning Teams for Reflective Adaptation for Diabetes and DepressionThe study will randomize 54 primary care practices to two intervention and a comparison groups. Both interventions will involve an on-site Improvement Facilitator who will assist the practice in forming an Improvement Team, using rapid-cycle tests of change, and implementing chronic care office systems for type 2 diabetes and depression. One intervention is based on complexity science and the other is a traditional QI intervention. | Hypertension | NA | À vérifier | United States | À vérifier |
| VumerityThe investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy. | SEP | À vérifier | Immunomodulation | United States | À vérifier |
| Closed Loop Trans-Auricular Vagus Nerve Stimulation SystemThe goal of this clinical trial is to learn if stimulating the vagus nerve in combination with a motor task in people with multiple sclerosis can improve motor function. The main questions it aims to answer are: * Is stimulating the vagus nerve safe and feasible after demyelinating episodes? * Does a paired motor task with vagus nerve stimulation improve motor function with someone who has multiple sclerosis? Researchers will compare active vagus nerve stimulation to a sham stimulation to see if the paired vagus nerve stimulation can improve motor control. Participants will: * Come in for study visits over a six month period. Study visits are three times weekly for the first month, then single follow up visits at two, three, and six months. * During study visits, participants will complete 30 minutes of the paired vagus nerve stimulation with a motor task, specifically the grooved peg test. * At various timepoints throughout the study, motor, disability, and neurophysiological assessments will be administered, including the Timed 25-Foot Walk Test, Expanded Disability Status Scale (EDSS), Upper Extremity portion of the Fugl-Meyer Assessment, Dellon-Modified Moberg Pick-Up Test, Multiple Sclerosis Impact Scale-29 (MSIS-29), motor evoked potentials (MEPs), and visual evoked potentials (VEPs). MRI assessments will also be performed to evaluate exploratory imaging metrics of potential remyelinative efficacy. | SEP | Non applicable | Remyélinisation | United States | À vérifier |
| HEADS-UP — Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding PainThe goal of this study (supported by and included in the NIH HEAL Initiative: https://heal.nih.gov/) is to learn if a fully virtual study comparing two telehealth group interventions for adolescents with migraine is feasible and acceptable: 1. Telehealth group mindfulness-based intervention 2. Telehealth group headache education | Migraine | Non applicable | Traitement symptomatique | United States | À vérifier |
| OzanimodThis study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod. The study will collect and review reported cases of PML to describe patient characteristics and estimate how often PML occurs among people treated with ozanimod. Researchers will assess factors that may be associated with the occurrence of PML, such as age, duration of ozanimod exposure, prior immunosuppressant use, lymphopenia, and JCV antibody status . | SEP | À vérifier | À vérifier | United States | À vérifier |
| Sweat Evaporimeter MeasurementThe investigators hypothesize that measurement of beta adrenergic induced sweat rate using an evaporimeter can accurately and reliably determine different levels of CFTR dysfunction within a spectrum of patients expressing various degrees of cystic fibrosis disease. The investigators overall goal is to determine whether the evaporimeter technique of measuring beta-adrenergic induced sweat rate is capable of accurately and reliably identifying different levels of CFTR dysfunction, as a prerequisite before advancing this technique as biomarker assay into clinical trials. | SEP | Non applicable | À vérifier | United States | À vérifier |
| OzanimodThis study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod. The study will collect and review reported cases of PML to describe patient characteristics and estimate how often PML occurs among people treated with ozanimod. Researchers will assess factors that may be associated with the occurrence of PML, such as age, duration of ozanimod exposure, prior immunosuppressant use, lymphopenia, and JCV antibody status . | SEP | Phase 3 | À vérifier | United States, Australia, Italy, Mexico, Poland, Portugal, Puerto Rico, Romania, Spain, Taiwan, Turkey (Türkiye) | À vérifier |
| adaptive DBS (aDBS)This is an interventional study of a cohort of patients with PD treated with DBS, and already utilizing adaptive DBS (dual threshold mode). In Aim 1, we will obtain baseline sleep and basal ganglia physiology data to inform aDBS parameter changes. Aim 2 involves 15 nights of in-home monitoring of subjective and objective sleep quality, during which participants will use 3 different sleep-tailored aDBS settings at night only. Participant preference among these 3 settings will determined the 'optimized sleep-tailored aDBS mode'. Participants will undergo repeat polysomnography, while in the optimized sleep-tailored aDBS mode, to compare aDBS behavior and sleep architecture to the baseline (Aim 1) sleep study. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and AtorvastatinThe goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is: * Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment * Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages. * Participants will take atorvastatin (daily pill) alongside their standard treatment. | Cancer | Phase 2 | United States | À vérifier | |
| Clemastine Fumarate Combined With Engineered SoundThe goal of this clinical trial is to determine the efficacy of Clemastine Fumarate in the presence of engineered sound to treat age-related central auditory processing disorder (CAPD). This disorder impacts 800M patients worldwide, including \~1/3 people over 40 years of age and \~1/2 people over 65, resulting in an inability to hear in noisy environments. The primary hypothesis this study aims to test is: engineered sound, driving localized neural circuit activity, will enable Clemastine Fumarate to mature Oligodendrocyte cells and thus remyelinate these activated neural circuits. This Localized Oligodendrocyte Optimization Therapy (LOOT) was highly effective in preclinical animal studies so this clinical trial aims to answer if this therapy will translate to humans. The study is an adaptive design intended to compare the efficacy of the drug in the presence or absence of the engineered sound for improving hearing in noise ability. Trial participants will be tested for hearing thresholds and ability to isolate a sound signal from background noise. If they meet the inclusion criteria, they will be enrolled into one of the four arms of the study and undergo the proposed one-month treatment (drug and sound or respective placebos). After the treatment period, trial participants will be tested again for hearing thresholds and their ability to isolate s sound source of interest from background noise. The hypothesis to be tested in this clinical trial is that the one-month treatment will significantly improve the participant's ability to isolate a sound source of interest from background noise. The design has four arms, drug+sound, placebo+sound, drug+white noise, and placebo+white noise. Based on our preclinical data, control arms are all expected to show identical results, thus our adaptive design includes interim analyses to allow for dropping of two of the three placebo arms should the preclinical results be replicated as anticipated. We will also monitor each participant's general health during the duration of the clinical trial, which will be done by performing a number of blood tests, an EKG and a general physical before and after the one-month treatment period. We expect no significant changes since participants will take the drug for the one-month period at dosages already demonstrated safe in several Phase II studies of multiple sclerosis. Similarly, the engineered sound will be listened to for one hour per day during this month at sound intensities well below threshold that might cause noise-induced hearing damage. | SEP | Phase 1/2 | Remyélinisation | United States | À vérifier |
| Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)Immune checkpoint inhibitors (ICIs) are a class of medications that are now standard in the treatment of melanoma. These are standard therapy for melanoma, but long-term side effects on disease in the heart arteries is poorly understood. In this study, melanoma patients receiving ICIs for the first time will undergo a coronary computed tomography angiography (CCTA) scan. CCTA results will be analyzed by the FDA-approved Cleerly TM image analysis pipeline. Patients with disease in their heart arteries will be randomized to usual care or aggressive lipid lowering therapy. Those in the aggressive lipid lowering therapy arm will be seen by a cardiologist and placed on standard lipid lowering medications with a goal of achieving an LDL-C ≤ 55mg/dL. Follow-up CCTA scans will occur at 12-month and 24-month timepoints. The primary outcome of interest will be differences in LDL-C levels between the two arms at the 12-month timepoint. The secondary outcome of interest will be the differences in total plaque volume between the two arms at the 12-month timepoint. | Maladie coronarienne | Non applicable | United States | À vérifier | |
| CD19x22 CAR TThis study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL. | SEP | Phase 1 | Thérapie cellulaire + Immunomodulation | United States | À vérifier |
| aDBSThe investigators conduct a prospective study to evaluate the effects of exercise on Parkinson's Disease brain biomarkers detected with the PerceptTM PC neurostimulator. | Parkinson | À vérifier | À vérifier | United States | À vérifier |
| Temporary implatation of large-scale intracranial electrode.This study is being done to the determine the ability and utility of using the Neuropixels probes in the human brain. A Neuropixels probe will be inserted into and removed from the brain of awake human patients who are undergoing awake Deep Brain Stimulation (DBS) surgery. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| OzanimodThis study will evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare brain infection caused by John Cunningham virus (JCV), among people with multiple sclerosis who have been treated with ozanimod. The study will collect and review reported cases of PML to describe patient characteristics and estimate how often PML occurs among people treated with ozanimod. Researchers will assess factors that may be associated with the occurrence of PML, such as age, duration of ozanimod exposure, prior immunosuppressant use, lymphopenia, and JCV antibody status . | SEP | Phase 4 | À vérifier | United States | À vérifier |
| Ocrelizumab at homeThe goal is to assess the safety and effectiveness of home ocrelizumab infusion. | SEP | Phase 4 | À vérifier | United States | À vérifier |
Essais cliniques
20| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab at home | SEP | Phase 4 | NCT04650321 | Home Based Infusions for Ocrelizumab | RECRUITING |
| Ozanimod | SEP | Phase 4 | NCT06529406 | COAST — Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod | RECRUITING |
| Temporary implatation of large-scale intracranial electrode. | Parkinson | Non applicable | NCT06778135 | Neocortical Microarchitecture of Executive Function | RECRUITING |
| aDBS | Parkinson | À vérifier | NCT06296810 | Adaptive DBS to Offset STN Dysregulation During Exercise in PD | ACTIVE_NOT_RECRUITING |
| CD19x22 CAR T | SEP | Phase 1 | NCT06559189 | CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT02980042 | Safety of Switching From Rituximab to Ocrelizumab in MS Patients | COMPLETED |
| Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran) | Maladie coronarienne | Non applicable | NCT07704918 | Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma | RECRUITING |
| Clemastine Fumarate Combined With Engineered Sound | SEP | Phase 1/2 | NCT07304024 | CAPD-LOOT — A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound | RECRUITING |
| Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | Cancer | Phase 2 | NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | NOT_YET_RECRUITING |
| adaptive DBS (aDBS) | Parkinson | Non applicable | NCT07808346 | Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease | RECRUITING |
| Ozanimod | SEP | Phase 3 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | RECRUITING |
| Sweat Evaporimeter Measurement | SEP | Non applicable | NCT01708655 | Sweat Evaporimeter Measurement | COMPLETED |
| Ozanimod | SEP | À vérifier | NCT07732907 | Risk of Progressive Multifocal Leukoencephalopathy Among Patients With Multiple Sclerosis Exposed to Zeposia | RECRUITING |
| HEADS-UP — Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain | Migraine | Non applicable | NCT07513662 | HEADS-UP — Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain | NOT_YET_RECRUITING |
| Closed Loop Trans-Auricular Vagus Nerve Stimulation System | SEP | Non applicable | NCT06641271 | Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery | ENROLLING_BY_INVITATION |
| Vumerity | SEP | À vérifier | NCT07757568 | Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity) | ACTIVE_NOT_RECRUITING |
| ULTRA-DM/MDD — Using Learning Teams for Reflective Adaptation for Diabetes and Depression | Hypertension | NA | NCT00414986 | ULTRA-DM/MDD — Using Learning Teams for Reflective Adaptation for Diabetes and Depression | COMPLETED |
| Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome | Myopathies | À vérifier | NCT03736174 | Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome | UNKNOWN |
| 3, 4-Diaminopyridine | Myasthénie | À vérifier | NCT01825395 | Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome | APPROVED_FOR_MARKETING |
| Risk Factors in Early Multiple Sclerosis | SEP | À vérifier | NCT03586986 | Risk Factors in Early Multiple Sclerosis | UNKNOWN |
Publications
23| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Ozanimod | Comprehensive Analysis of Ozanimod-Related Adverse Events Based on the FAERS Database. | World journal of oncology | ||
| Ozanimod | Novel Agents on the Therapeutic Horizon For Paediatric Inflammatory Bowel Diseases: An Analysis of Clinical Trials Registries. | Paediatric drugs | ||
| Ozanimod | Ozanimod and other sphingosine-1-phosphate receptor 1 modulators normalize neuropathic injury-enhanced inhibition of central lateral amygdala neurons expressing corticotropin-releasing hormone. | Neuropharmacology | ||
| Tecfidera | Periconceptional nonsteroidal anti-inflammatory drug use, folic acid intake, and the risk of spina bifida. | Birth defects research | ||
| Tecfidera | Dimethyl fumarate modulates the regulatory T cell response in the mesenteric lymph nodes of mice with experimental autoimmune encephalomyelitis. | Frontiers in immunology | ||
| Risk Factors in Early Multiple Sclerosis | Longitudinal evolution of JC virus serological index in multiple sclerosis patients treated with natalizumab: Observational dynamics in a decade-spanning real-world cohort (2014-2024). | Clinical neurology and neurosurgery | ||
| Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome | [Diseases and overuse injuries of the lower extremities in long distance runners]. | Zeitschrift fur Rheumatologie | ||
| Utilization of High Frequency Ultrasound to Diagnose Chronic Exertional Compartment Syndrome | Radiological Prevalence of Popliteal Artery Entrapment in Individuals With Anterior Leg Compartment Chronic Exertional Compartment Syndrome. | Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine | ||
| Tecfidera | Leveraging Signal Detection and Mendelian Randomization in Spontaneous Reporting for Post-Marketing Surveillance of Drug- Induced Amnesia. | Current medicinal chemistry | ||
| Tecfidera | Shared Genomic Architecture Between Schizophrenia and Multiple Sclerosis Identifies an Un-Drugged HCAR1 Neuroimmune Checkpoint. | bioRxiv : the preprint server for biology | ||
| Vumerity | Comparative Effectiveness of Diroximel Fumarate vs. Dimethyl Fumarate in Persons with Multiple Sclerosis: A US Claims Analysis of Relapse Outcomes. | Advances in therapy | ||
| Risk Factors in Early Multiple Sclerosis | Semaglutide as a potential neuroprotective agent for neurological and neurodegenerative disorders: Mechanisms, preclinical evidence, and translational challenges and opportunities. | Molecular biology reports | ||
| Risk Factors in Early Multiple Sclerosis | The impact of multiple sclerosis on social determinants of health: Results from the SocialMS study. | Multiple sclerosis and related disorders | ||
| Risk Factors in Early Multiple Sclerosis | AI-based predictive biomarkers for chronic neurological diseases: the rAIdD prospective, multicenter, observational study protocol. | Frontiers in neurology | ||
| Risk Factors in Early Multiple Sclerosis | Targeting progressive multiple sclerosis: Toward mechanism-informed precision medicine. | Journal of internal medicine | ||
| Risk Factors in Early Multiple Sclerosis | The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis. | Neurology(R) neuroimmunology & neuroinflammation | ||
| Risk Factors in Early Multiple Sclerosis | Pontine Autosomal Dominant Microangiopathy with Leukoencephalopathy in a Hispanic Man Without a Family History. | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association | ||
| 3, 4-Diaminopyridine | The impact of experimental variables in twitch tension recording on triphasic action of phospholipase A neurotoxins at the neuromuscular junction and acetylcholine release. | Toxicon : official journal of the International Society on Toxinology | ||
| 3, 4-Diaminopyridine | Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience. | Journal of neurology | ||
| Risk Factors in Early Multiple Sclerosis | Age-associated B-cells across the rheumatoid arthritis continuum: from early immunopathogenesis to comorbidities. | Frontiers in aging | ||
| Risk Factors in Early Multiple Sclerosis | Lifetime exposure to shift work and risk of multiple sclerosis: retrospective and prospective cohort studies in UK Biobank. | Occupational and environmental medicine | ||
| Risk Factors in Early Multiple Sclerosis | Current perspectives on the pathogenesis of multiple sclerosis: A minireview. | Endocrine regulations | ||
| Risk Factors in Early Multiple Sclerosis | Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache. | European journal of neurology |